Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance

Journal of Cardiovascular Medicine

Volumn 11, Issue 5, 2010, Pages 386-388

  Foley, Paul W X ^a   Hamilton, Malcolm S ^b   Leyva, Francisco ^c  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Bortezomib; Cardiovascular magnetic resonance; Heart failure

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; GADOLINIUM PENTETATE; METHYLPREDNISOLONE; VINCRISTINE;

ADULT; ANKLE EDEMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; DYSPNEA; FEMALE; HEART FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; IMAGE ENHANCEMENT; LUNG EDEMA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; SCAR FORMATION; SYSTOLIC DYSFUNCTION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FATAL OUTCOME; FEMALE; FIBROSIS; GADOLINIUM; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE MYELOMA; MYOCARDIUM; PYRAZINES;

EID: 77950274235     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32832f3ff2     Document Type: Article

References (16)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
2. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
3. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a nonsmall cell lung cancer patient: a case report. BMC Cancer 2006; 6:129.
4. Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol 2008; 88:219-222.
5. Orciuolo E, Buda G, Cecconi N, Galimberti S, Versari D, Cervetti G, et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 2007; 138:396-397.
6. Weekes J, Morrison K, Mullen A, Wait R, Barton P, Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003; 3:208-216.
7. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen E-L, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992-2002.
8. Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004; 43:2260-2264.
9. Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Heart J 2007; 28:1242-1249.
10. McCrohon JA, Moon JJC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJS, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003; 108:54-59.
11. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111:186-193.
12. Catalano O, Antonaci S, Moro G, Baldi M, Cobelli F, Opasich C. Contrastenhanced cardiac magnetic resonance in a patient with chemotoxic cardiomyopathy. J Cardiovasc Med 2007; 8:214-215.
13. Perel RD, Slaughter RE, Strugnell WE. Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma. J Cardiovasc Magn Reson 2006; 8:789-791.
14. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging: a pilot study. Am Heart J 2001; 141:1007-1013.
15. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90:29-34.
16. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal D. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008; 10:5.